Published: June 2025 | Last updated: May 2026
When will the chlamydia vaccine actually be available?
Realistically no earlier than late 2028, with broad public access more likely in 2029 or 2030. The Sanofi mRNA candidate leads, in a Phase 1/2 study that began in spring 2025 after winning FDA Fast Track in March 2025. Phase 3 efficacy trials and FDA review come next. Until then, regular testing is the reliable way to catch chlamydia early.
Chlamydia is the most reported bacterial sexually transmitted infection in the United States, and most of the people carrying it do not know. A vaccine would change how the public-health system handles all of that. The encouraging news is that the science has finally moved out of animal models and into human clinical trials. Three programs are in active development: a Sanofi-led mRNA vaccine that received U.S. FDA Fast Track designation in March 2025, the protein-based CTH522 candidate from Statens Serum Institut in Denmark, and a separate oral mucosal vaccine being studied at UT Health San Antonio with multi-year NIH funding.
The slower news is that public access is still several years out. This explainer covers where each candidate sits in the pipeline as of mid-2026, what the realistic timeline looks like if Phase 3 trials succeed, why bacterial STIs have been so much harder to vaccinate against than viral ones, and what to do in the meantime if you are sexually active, including how at-home chlamydia testing fits the picture.
Why a chlamydia vaccine would change public health
According to CDC STI surveillance data, chlamydia is the most commonly reported bacterial STI in the country, with more than 1.6 million cases reported in 2023, the most recent year with finalized surveillance data. Most of those infections are silent. The CDC's chlamydia fact sheet notes that most people carrying Chlamydia trachomatis have no symptoms at all, which is why annual screening is recommended for every sexually active woman under 25 and for older women and men with risk factors.
The cost of that silence is reproductive. Untreated chlamydia can ascend from the cervix into the upper genital tract and cause pelvic inflammatory disease, or PID. NIH's MedlinePlus notes that an untreated infection can spread to the uterus and fallopian tubes, leading to long-term pelvic pain, infertility, and ectopic pregnancy. In men, the same untreated infection can cause epididymitis and, less commonly, fertility problems.
A vaccine would not replace condoms, screening, or treatment. It would add a layer of protection upstream of all three. The clearest parallel is the HPV vaccine: when offered at routine adolescent visits, it has measurably reduced the incidence of HPV-associated cancers in vaccinated groups. Public-health modeling of a chlamydia vaccine projects similar long-term benefits, especially in the 15 to 24 age group, where most reported new diagnoses concentrate according to ongoing CDC surveillance.
In the U.S. the CDC reports more than 1.6 million cases each year. The <a href="https://www.who.int/news-room/fact-sheets/detail/chlamydia" target="_blank" rel="noopener noreferrer">World Health Organization estimates roughly 128.5 million new chlamydia infections in 2020</a> among adults aged 15 to 49 worldwide. Because so many infections are asymptomatic, the true incidence is widely thought to be substantially higher than what surveillance captures.
Where the research stands in 2026
The chlamydia vaccine pipeline went quiet for decades. Bacterial STIs are harder targets than viral ones, funding lagged, and earlier vaccine attempts in the 1950s and 1990s either failed in animal models or produced disappointing results in early human safety trials. Three current programs have moved the field forward.
Sanofi's mRNA chlamydia vaccine. The company, working with academic collaborators, is running a randomized, placebo-controlled Phase 1/2 clinical study, launched in spring 2025 after the U.S. FDA granted the candidate Fast Track designation in March 2025. The study is evaluating safety, immunogenicity, and dose in adults aged 18 to 29, with Phase 2 expansion cohorts following the initial Phase 1 safety readout. The candidate is designed to protect against both primary genital tract infection and reinfection. FDA Fast Track is a procedural flag that signals clinical priority to the agency; it does not guarantee approval, and Phase 3 results will determine the outcome.
CTH522 (Statens Serum Institut). CTH522 is a recombinant version of the chlamydia outer-membrane protein originally developed at Statens Serum Institut in Denmark. Phase 1 trials in healthy adults, including more recent work using adjuvants that boost the immune response, found the vaccine safe and able to generate both systemic IgG antibodies and mucosal antibody responses. Investigators have indicated the program is ready for Phase 2 evaluation. CTH522 has been in development longer than the Sanofi mRNA program and represents the established protein-subunit approach to the same target.
The UT Health San Antonio oral mucosal program. The third program, led by researchers at UT Health San Antonio, is funded by an 11 million dollar five-year NIH grant awarded in 2024. Its oral candidate, named intrOv, is a live attenuated strain built on an unexpected finding: when chlamydia colonizes the gastrointestinal tract it becomes non-pathogenic yet still primes protective immunity at distant sites, including the genital tract. By inducing IgA antibodies and tissue-resident memory T cells, the approach aims to block the bacteria at the cervix, urethra, or rectum before they cross into deeper tissue. The program sits behind the Sanofi and CTH522 candidates on the regulatory timeline.
Several earlier candidates from other research groups remain in animal-model or preclinical phases, including a recombinant CPAF (chlamydial protease-like activity factor) vaccine at the University of North Carolina, and subunit candidates targeting MOMP (the major outer membrane protein of C. trachomatis) and polymorphic membrane proteins. None are within five years of public availability based on currently published data.
One unexpected proof of concept for the field came from veterinary medicine. Australian koala populations have been hit hard by ocular and reproductive chlamydia, and trial vaccines using a related outer-membrane protein produced measurable reductions in severe disease in vaccinated animals. Marsupial biology is not a perfect human analog, but the mucosal immune response patterns gave human vaccine developers more confidence that the same antigen targets could work in people.
How an mRNA chlamydia vaccine would work
The basic mRNA strategy is the same one used in the COVID-19 vaccines that received emergency authorization in 2020. Lipid nanoparticles deliver a stretch of messenger RNA into the body's own cells. The cells read that mRNA and produce a specific bacterial protein, and the immune system learns to recognize and respond to that protein. If a real Chlamydia trachomatis infection happens later, antibodies and memory T cells are already trained to neutralize it.
For chlamydia, the antigen targets are unlike anything in previously approved vaccines. The bacterium is intracellular, meaning it lives inside human cells, and it has a complex two-form life cycle: an infectious extracellular form called the elementary body, and a replicative intracellular form called the reticulate body. A vaccine has to teach the immune system to attack one or both forms without triggering the overactive inflammatory response that hurt earlier whole-cell vaccine attempts in the 1960s.
Modern candidates target proteins from the bacterial outer membrane, the secretion system the bacterium uses to enter human cells, or both. The Sanofi mRNA candidate uses a multi-antigen approach, which means it teaches the immune system to recognize more than one bacterial protein at once. That makes immune escape harder and is one of the reasons researchers are more optimistic now than they were 20 years ago. Mucosal candidates, like the UT Health San Antonio program, aim to add a second layer of what immunologists call sterilizing mucosal immunity: IgA antibodies and tissue-resident memory T cells right at the cervix, urethra, or rectal mucosa, where the bacteria first arrive.
Chlamydia trachomatis alternates between two shapes during infection. The elementary body is the small, tough, infectious form that travels between cells. Once inside a cell, it converts into the larger reticulate body, which hides from antibodies and replicates. A successful vaccine has to mount an immune response that can hit the elementary body before it gets inside a cell, and prime cell-mediated immunity to clear infected cells. This is harder than the single-target challenge most viral vaccines face.
Why antibiotics alone are not enough anymore
Antibiotics still work for most chlamydia infections, and the NHS notes the infection is usually cleared with a short course of antibiotics. The CDC's first-line recommendation is doxycycline 100 mg by mouth twice daily for seven days, with single-dose azithromycin reserved for specific cases such as pregnancy. The problem is not that the pills fail outright. It is that the system around them is reactive rather than preventive, and chlamydia exploits every gap.
The first gap is reinfection. The CDC explicitly states that the majority of positive tests after treatment are not treatment failures but reinfections from untreated partners or new exposures. People who follow the protocol perfectly can still test positive again within months because the partner did not get treated, or because a new partner brought the infection back. That is why the CDC recommends a routine retest at three months regardless of partner-treatment status.
The second gap is silent spread. Many chlamydia infections cause no symptoms at all, and the incubation window can stretch up to three weeks. Without symptoms, people do not test, do not treat, and unintentionally pass the infection along to the next partner without ever knowing they had it.
The third gap is biology. Some research suggests Chlamydia trachomatis can enter a persistence state inside host cells, a slowed-down form that is harder for antibiotics to eliminate and harder for the immune system to detect. The clinical significance of persistence is still debated, and most experts agree that recommended antibiotic regimens do clear the active infection in the vast majority of cases. But persistence helps explain why some patients describe lingering symptoms even after a confirmed treatment course, and why some test as positive months later without an obvious new exposure.
A vaccine that primes mucosal immunity at the cervix, urethra, and rectum would shift the prevention strategy from reactive to proactive at the very tissues where transmission happens.
The majority of posttreatment infections do not result from treatment failure but rather from reinfection caused by failure of sex partners to receive treatment or initiation of sexual activity with a new infected partner.
The realistic development timeline
Vaccine timelines are easy to draw and hard to predict. Phase 2 cohorts can stall on dose-optimization questions, Phase 3 trials require large numbers of participants and meaningful event counts, and FDA review itself takes months even with Fast Track. Fast Track can be paired with a rolling submission and, in some cases, an Accelerated Approval pathway, though none of those shortcuts skip the Phase 3 efficacy testing that ultimately decides whether a vaccine reaches the public. The clearest near-term checkpoint to watch is Phase 2 efficacy data from the Sanofi candidate, expected around 2027 to 2028.
Based on currently published trial information, the practical path looks like this:
| Stage | Approximate window | What happens |
|---|---|---|
| Phase 1/2 | 2025 to 2026 | Combined safety, dose-escalation, and immunogenicity study in adults aged 18 to 29; Phase 1 safety portion leads into dose-expansion Phase 2 cohorts. |
| Phase 3 | 2026 to 2028 | Large efficacy trial measuring real-world infection rates in vaccinated versus placebo groups across multiple continents. |
| FDA submission and review | 2028 to 2029 | Biologics License Application filed and reviewed under Fast Track. Six to ten months minimum. |
| Initial public access | 2029 to 2030 | Likely restricted at first to higher-risk groups (adolescents, young adults, people with frequent partner change). |
| Routine adolescent vaccination | 2030 onward | Inclusion in CDC immunization schedules following ACIP recommendation, similar to the HPV rollout pattern. |
What the vaccine would and would not protect against
The candidates currently in trials are designed specifically against Chlamydia trachomatis, the bacterium that causes the common genital STI and ocular trachoma. A successful vaccine would not protect against gonorrhea, syphilis, herpes, HIV, hepatitis B, hepatitis C, trichomoniasis, or HPV. Each of those infections has its own pathogen, its own immune targets, and its own vaccine timeline.
This matters for two practical reasons. First, co-infection is common: people who have chlamydia have an elevated risk of also carrying gonorrhea, and the CDC recommends testing for both together when one is suspected. Second, the protection a chlamydia vaccine would confer, however good, is narrow. Anyone sexually active will still need regular screening for the other infections, and condoms remain the most efficient single intervention to reduce broad STI transmission.
It is worth setting expectations on effectiveness now. Published real-world effectiveness data for approved STI vaccines, with the HPV vaccine as the primary published benchmark, has generally run in the 60 to 90 percent range, depending on the vaccine, strain coverage, and population. That is enormous from a public-health standpoint and meaningful for any individual, but it is not zero risk. One open question is whether the eventual vaccine will protect equally well against all anatomical sites of infection. Chlamydia can establish itself in the cervix, urethra, rectum, throat, or eye. Mucosal immunity is generally site-specific, which is one reason researchers are interested in oral and intranasal delivery routes that may produce broader mucosal coverage than an intramuscular shot can.
Test for chlamydia while the pipeline runs
The vaccine timeline does not change what works today. This article is published by stdrapidtestkits.com, which sells at-home STI testing kits, and we recommend products based on fit for the reader's concern rather than commercial benefit. The kit below covers the two co-occurring bacterial infections discussed in the section above and is the practical layer of protection available while the candidates above work through their trials.
Why a chlamydia vaccine has taken so long
Several factors converged to slow this pipeline for decades. Biology came first. Unlike viruses, which the immune system can often clear with antibodies that block free virions, Chlamydia trachomatis spends most of its life cycle hidden inside human cells, where antibodies cannot reach it. Earlier whole-cell vaccine attempts in the 1960s using formalin-inactivated chlamydia produced an immune response but also, paradoxically, worsened disease when vaccinated participants were later naturally exposed. That phenomenon, now understood as vaccine-enhanced disease, essentially froze the field for two decades. Modern vaccinology, with better tools to characterize T-cell and antibody responses and a deeper understanding of mucosal immunity, has only recently been able to design candidates that avoid the same trap.
Funding lagged behind biology for different reasons. Vaccine programs follow public-health priority, and bacterial STIs, despite their staggering incidence, have not historically received funding at the level of HIV, HPV, or pneumococcal disease. Because chlamydia has long been considered treatable with antibiotics, it stayed lower on government and industry priority lists than diseases without a cure. Public funding picked up substantially after the 2010 World Health Organization global STI strategy and again after the 2016 declaration of antimicrobial-resistant gonorrhea as a priority pathogen, both of which redirected attention toward STI vaccine science as a whole.
Technical capability also took time to catch up. The genomic and proteomic tools needed to identify consistent, protective antigens did not exist in usable form until the 2000s. The MOMP gene was first sequenced in the late 1980s, but the ability to design multi-antigen, mRNA-encoded vaccines is essentially a post-2015 development. The same lipid-nanoparticle and mRNA platform that made COVID-19 vaccines possible in months also gave the chlamydia field a tool it had been missing for half a century. Without that platform, the Sanofi candidate currently in Phase 1/2 testing would not exist.
Stigma played a quieter role. Vaccine candidates targeting sexually transmitted infections have historically attracted less industry investment than candidates targeting respiratory or pediatric infections, despite similar or larger public-health burdens. That has shifted as the HPV vaccine demonstrated commercial viability and as the antimicrobial-resistance crisis pushed regulators to take bacterial STIs more seriously.
Before mRNA, chlamydia vaccine designers had to grow whole bacteria or purify individual proteins, both error-prone processes that gave the field decades of false starts. The lipid-nanoparticle and mRNA platform validated by COVID-19 vaccines in 2020 lets researchers encode multiple bacterial antigens at once and update the design quickly when trial data points to a better target. That capability is the single biggest reason a chlamydia vaccine is now in human trials, not animal models.
Who will get the vaccine first when it arrives
When a chlamydia vaccine is approved, it will not appear on every pharmacy counter the same week. Like the COVID-19 and HPV rollouts, access will be staged based on age, exposure risk, and public-health priorities.
The clearest signal of priority comes from the trial population itself. Sanofi's Phase 1/2 study enrolls adults aged 18 to 29, which is also the demographic where chlamydia hits hardest. The CDC notes that sexually active women younger than 25 should already be screened annually, reflecting the same age skew. The first vaccine recommendations, when they come, are likely to mirror that age band before broadening.
Beyond age, expect rollouts to focus on people with frequent partner changes, communities with limited access to routine STI care, and clinical settings where high-volume testing already happens. Modeling work on potential public-health impact suggests that targeting the highest-incidence groups first generates the largest reduction in onward transmission. Fertility considerations will probably push earlier rollout to people assigned female at birth, since pelvic inflammatory disease and tubal scarring drive much of the long-term harm from repeat infections. Men, trans, and nonbinary people are not afterthoughts in the science: trials are designed to capture immune responses at multiple anatomical sites, and the vaccine is intended to reduce transmission across the whole sexual network.
- Sexually active adults aged 18 to 29, mirroring the trial enrollment population.
- People with a history of repeat chlamydia infection or frequent partner changes.
- College and university student health programs.
- Sexual-health and family-planning clinics with high-volume STI screening.
- Communities with limited access to ongoing STI screening and follow-up.
What the vaccine will not do for you
Even an excellent vaccine has limits worth setting now, before approval headlines arrive.
How to protect yourself until the vaccine arrives
The practical playbook for the next few years is the same as the playbook for the last few years, just with more discipline.
Test on a schedule that matches your activity. The CDC recommends annual chlamydia screening for sexually active women under 25 and for older women with risk factors (new partners, multiple partners, a partner with an STI). Men who have sex with men should be screened at least annually for chlamydia at the anatomic sites of exposure. Anyone in a new relationship or with a recent exposure should test sooner than annually.
Test one to two weeks after a new exposure. Lateral-flow swab tests detect infection once bacterial load is high enough; testing immediately after sex can produce a false negative because the bacterial population has not yet built up.
Use condoms consistently with new partners. Condoms reduce but do not eliminate transmission of chlamydia, gonorrhea, syphilis, and HIV. They are still the single best behavioral tool for reducing acquisition of the bacterial STIs that have no vaccine yet, and a panel of at-home STI test kits can screen for several of those infections at once.
Treat partners when you test positive. Expedited partner therapy is legal in most U.S. states and allows clinicians to prescribe treatment for a sexual partner without requiring that partner to be seen separately. It is one of the most effective interventions for breaking reinfection cycles.
If symptoms appear, do not wait. Unusual discharge, pelvic pain, painful urination, post-coital bleeding, or testicular pain warrants a clinic visit. Home tests are a useful screening tool, especially for asymptomatic checks; clinical evaluation is appropriate when something feels wrong.
Retest at three months, not four weeks. The CDC recommends a test of reinfection roughly three months after treatment, because being treated once does not produce lasting immunity, and reinfection from an untreated partner is the single most common cause of a repeat positive. The CDC explicitly does NOT recommend an immediate four-week test of cure in nonpregnant adults, because nucleic-acid amplification tests can pick up DNA fragments from already-killed organisms and produce false positives.
FAQs
- Can I get the chlamydia vaccine now?
- No. The leading candidates are in active clinical trials. The Sanofi mRNA candidate is in a combined Phase 1/2 study launched in spring 2025, the CTH522 protein candidate has finished Phase 1 and is preparing for Phase 2, and the UT Health San Antonio oral candidate is earlier in development. Realistic FDA approval is no earlier than late 2028. If a website claims to ship you a chlamydia vaccine today, it is not a real product.
- What does FDA Fast Track designation actually mean?
- Fast Track lets Sanofi submit trial data to the FDA in rolling batches as it is generated, rather than waiting until the full study is complete, and triggers more frequent meetings between the company and the agency to discuss the development program. It does not skip Phase 3, lower safety standards, or shortcut adverse-event monitoring. Sanofi's chlamydia candidate received Fast Track status in March 2025.
- Will the vaccine be a single shot or multiple doses?
- Expect at least two doses based on the current trial design. The exact schedule will be confirmed by Phase 3 results and FDA labeling at approval. Most current mRNA vaccines use a prime-plus-boost regimen.
- If I have already had chlamydia, will the vaccine still help me?
- Yes. Having chlamydia once does not confer durable immunity, which is part of why repeat infections are so common. The Sanofi candidate is specifically designed to protect against both primary infection and reinfection. People with a history of chlamydia are likely to be among the priority groups when access opens up.
- Will the chlamydia vaccine prevent every infection?
- Unlikely, and it is worth being specific about what prevent means here. The clinical trial endpoint will probably be a statistically significant reduction in new infections across the trial population, not elimination. For an individual person, the expected protection is meaningful, comparable to HPV vaccine coverage rates, but not absolute. After vaccination, routine screening following a possible exposure is still the right call.
- Will men and women both be eligible?
- Both are eligible. Trials are enrolling adults aged 18 to 29 of any sex. Male, female, trans, and nonbinary participants can all contribute to and benefit from the program. Initial public access will probably target adolescents and young adults regardless of sex, with female-priority emphasis driven by the fertility consequences of untreated infection.
- Can I sign up for a chlamydia vaccine trial?
- Possibly. The current Phase 1/2 trials enroll sexually active adults aged 18 to 29 at participating research centers. Trial participants commit to follow-up visits, may receive a placebo, and the protective benefit is not guaranteed. ClinicalTrials.gov lists the full eligibility and site information for any active study.
- Will insurance cover it once approved?
- Vaccines recommended by the Advisory Committee on Immunization Practices and added to the CDC schedule are typically covered by most insurance plans without cost-sharing under the ACA preventive-services rules. The HPV vaccine is the closest analog and has been covered that way since 2010.
- U.S. Centers for Disease Control and Prevention. STI Statistics surveillance landing page: reported case counts for chlamydia and other STIs, including the more-than-1.6-million reported chlamydia cases in 2023.
- U.S. Centers for Disease Control and Prevention. Chlamydia: fact sheet on the asymptomatic majority pattern, screening recommendations (annual screening for sexually active women under 25), and treatment.
- U.S. Centers for Disease Control and Prevention. STI Treatment Guidelines, Chlamydial Infections: doxycycline 100 mg twice daily for 7 days as first-line, retesting guidance at three months, and the reinfection-versus-failure framing of posttreatment positives.
- U.S. National Library of Medicine, MedlinePlus (NIH). Chlamydia infections: complications of untreated infection including pelvic inflammatory disease, infertility, and ectopic pregnancy.
- World Health Organization. Chlamydia fact sheet: estimated 128.5 million new infections in 2020 among adults aged 15 to 49 worldwide, asymptomatic profile, and reproductive complications.
- Sanofi press release, March 26, 2025. Chlamydia vaccine candidate granted Fast Track designation by the U.S. FDA; mRNA Phase 1/2 randomized study in adults aged 18 to 29 targeting primary infection and reinfection.
- UT Health San Antonio. NIH grant of more than 11 million dollars (five-year U01) awarded in 2024 for a novel oral chlamydia vaccine candidate, intrOv, developed from gastrointestinal-colonization research.
- NHS. Chlamydia: symptoms, testing, and treatment overview. General clinical reference for transmission routes, the asymptomatic majority pattern, and standard antibiotic treatment.
